CEACAM1 immune agonistic antibodies to fight cancer

Ymmunobio is at the forefront of developing innovative cancer therapies, particularly focusing on gastrointestinal (GI) cancers. The company is pioneering a first-in-class antibody-drug conjugate (ADC) known as YB-800, which targets a newly identified receptor in oncology. This fully humanized antibody is designed to selectively bind to tumor cells while sparing healthy tissue, a significant advancement in precision cancer treatment. Ymmunobio's research is grounded in a comprehensive analysis of a large tumor bank, which has informed their approach to developing transformative therapeutics aimed at solid tumors.

In addition to YB-800, Ymmunobio is advancing several other candidates within its pipeline, including bi-specific candidates YB-800BS1 and YB-800BS2, as well as radio-labeled candidates YB-800R1 and YB-800R2. These candidates are being developed for various indications in solid tumors, with the radio-labeled versions also serving as diagnostic tools to identify primary tumors and their metastases. Ymmunobio's commitment to preclinical breakthroughs and its distinguished team of scientific leaders position the company as a key player in the evolution of cancer and autoimmune disease treatments.

Switzerland

Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation.

Ymmunobio

Company Details